Ascentage Pharma Announces 2026 AGM and Proposed Re-election of Directors

Ascentage Pharma Group International filed a Form 6-K on April 30, 2026, detailing its 2025 Annual Report and preparations for its upcoming Annual General Meeting (AGM) scheduled for May 20, 2026, in Suzhou, China. Key business for the AGM includes the re-election of retiring directors Dr. Wang Shaomeng, Dr. Lu Simon Dazhong, and Dr. David Sidransky. The company is also seeking shareholder approval for general mandates to issue and repurchase shares. Specifically, the Issuance Mandate would allow the board to allot up to 20% of issued shares, while the Repurchase Mandate would authorize the buy-back of up to 10% of issued shares. Additionally, the board proposed adopting a Third Amended and Restated Memorandum and Articles of Association to facilitate hybrid or electronic meetings. The company also announced the re-appointment of Ernst & Young as its auditor for the 2026 fiscal year, with an estimated audit fee of approximately RMB 5.1 million. No upcoming clinical trial result dates were specified in this regulatory filing.